Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $22.3 million.

  • Integra Lifesciences Holdings' Current Deferred Revenue rose 2355.15% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 2355.15%. This contributed to the annual value of $19.7 million for FY2024, which is 2102.51% up from last year.
  • Latest data reveals that Integra Lifesciences Holdings reported Current Deferred Revenue of $22.3 million as of Q3 2025, which was up 2355.15% from $22.1 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' Current Deferred Revenue's 5-year high stood at $22.3 million during Q3 2025, with a 5-year trough of $11.3 million in Q3 2021.
  • Moreover, its 5-year median value for Current Deferred Revenue was $16.2 million (2023), whereas its average is $16.0 million.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' Current Deferred Revenue crashed by 1132.92% in 2024, and later surged by 3581.01% in 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Current Deferred Revenue (Quarter) stood at $11.9 million in 2021, then soared by 35.0% to $16.1 million in 2022, then grew by 0.78% to $16.3 million in 2023, then increased by 21.03% to $19.7 million in 2024, then rose by 13.62% to $22.3 million in 2025.
  • Its Current Deferred Revenue stands at $22.3 million for Q3 2025, versus $22.1 million for Q2 2025 and $19.9 million for Q1 2025.